amongst high-growth off-shore earner see ep
move higher move lower
though valuat shl ann full remain
ow rel basi see neg ep revis
ep compound-annual-growth-rate market cap weight averag estim compar
look full go posit busi momentum
back posit product cycl core product growth robust though
per result street may disappoint composit
ow high-growth stock maintain high-growth multipl double-
digit top-lin growth on-going oper leverag growth data-driven strategi
posit driver watch news flow next competit bid
ow shl steadi ep trajectori fund risk known balanc sheet
potenti remain growth temper fee cut us pama germani
ebm though risk better understood australian privat
ow ann given balanc sheet strength emerg tailwind though
ebit need increas vs meet guidanc
macro pictur could begin cloud organ growth outlook
uw rhc given emerg australian margin challeng structur challeng
privat health/hospit industri remain leav risk expect
among smaller stock ivf stock offer valu prefer mvf mvf exit
strong momentum mvf vrt offer dividend yield
exhibit chang price target
prefer
price target convert cdi
morgan stanley research cdi disclosur page
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
analyst employ non-u affili regist
finra may associ person member may
subject nasd/nys restrict commun
subject compani public appear trade secur held
summari stock
refinitiv compani data morgan stanley research arrow denot ms estim either consensu
expect achiev npat slightli upper end guidanc
confid follow strong beat flu result see upsid
ebit target flu howev soft plasma lead
lower sustain growth
coh long-term opportun strongest coverag result
support servic upgrad revenu expect ci unit go backward
half still affect market share loss mri-compat devic
weak unit growth like short-term issu given sinc launch nucleu
profil europ us
rhc challeng off-shore busi seen relief franc beat
capio acquisit domin driver howev weak australian industri
like track risk remain due slow price growth across australian
strength core us busi rest world row mask well
improv gm took near-term back seat row devic soft dilut
data-gener invest result see long-term support
resuppli iv on-going oper leverag remain ow despit stock
price target recommend rel rest stock coverag list
downsid
commentari like influenc eur usd nitril input cost
impact trade tension outlook
shl reliabl within expect rang fund risk evid
adequ encapsul compani guidanc expect us hospit jv
drove higher us revenu growth german issu cycl april
mvf/vrt market share loss appar issu compani industri yet
demonstr return higher growth continu estim long-term cycl
growth see valu mvf vrt remain ow stock
manag inde deliv believ ew rate
warrant stage given uncertain impact knee mri remov
mb patient integr risk relat recent acquisit although
remain track
hl manag proactiv address issu though view ep uncertainti
remain gp recruit profil reach steadi state month
away given relianc larg uptick remain ew
ehe ebitda slightli behind mse guidanc reduc
mid-single-digit growth low- mid-single-digit growth occup
complianc issu drag stay ew
maintain uw industri condit remain challeng ii distribution-
centre-rel capital-expenditure build continu iii lost chemist
warehous contract yet take effect strategi need proven
api long-term strategi may intact near-term risk risen uw
rel smaller health care compani coverag prefer ow-rat
monash ivf see upsid
australian healthcar order prefer
exhibit larg cap order prefer
market cap aud mm
averag daili trade volume usd mm
valuat multipl last close
impli multipl ms price
morgan stanley research refinitiv consensu mean price close juli morgan stanley research estim note past perform guarante futur result result shown includ
transact cost nb usd report compani metric convert aud spot fx may differ estim
exhibit small cap order prefer
market cap aud mm
averag daili trade volume usd mm
valuat multipl last close
impli multipl ms price
morgan stanley research refinitiv consensu mean price close juli morgan stanley research estim note past perform guarante futur result result shown includ
transact cost nb usd report compani metric convert aud spot fx may differ estim
chang earn estim
expect australian healthcar stock maintain above-historical-level premium
broader view scarciti valu
think find pocket genuin valu industri remain challeng view
corrobor feedback investor larg choic investor
come hand large-cap offshore/usd-earn growth stock name
ow-rat still see posit catalyst ahead
best fundament long term highest multipl vs ew-rat fulli
valu risk downsid
updat earn estim valuat reflect top pick order
prefer ahead earn
earn model updat recent fx movement buy-back execut ytd
result ep chang respect
valuat use discount forward ep trade multipl
asx ex financi discount multipl move upon last ann
research public feb current appli ep
audusd deriv updat price target ann
earn model updat captur result led small ep
revis chang less result net debt
increas due recent invest activ clear skincar sigma
share transact well invest work capit
valuat base case price target fallen due
higher net debt dcf roll forward wacc fallen due
lower equiti compon lower share price bull bear case
valuat fallen respect
earn chang earn forecast year lower sale
beyond allow leverag
valuat base case price target increas
roll dcf net debt forward made adjust explain
wacc previous due updat debt/equ valu bull
bear case valuat increas respect
earn chang estim
valuat base case price target increas
roll dcf forward wacc unchang bull bear case
valuat increas respect
earn ehe provid trade updat ebitda report
onetim benefit recent govern fund announc ebitda expect
rang includ benefit one-off
govern fund boost royal commiss cost expect
earn due onetim fund benefit
howev earn move due lower base
normalis onetim fund benefit
valuat simplifi valuat methodolog set price target
equal base case previous assign probabl weight bull/base/bear
case think base case probabl outcom given compani
disclos cost associ royal commiss first announc
mid-sep base case decreas new price
target previou target bull bear case
valu previous respect
lower base case valu driven neg earn estim revis
earn updat hcp amortis medic centr segment captur
contract roll-off assum flat net interest expens go forward
led small increas net interest expens
valuat price target increas driven small
posit ep estim revis roll forward dcf
earn small posit revis ep estim vs
previou mse driven increas us patholog revenu growth increas
revenu europ expect favor condit us europ
forecast year
valuat base case price target increas
due posit earn estim revis updat capit expenditur assumpt
beyond forecast year better reflect need patholog busi wacc
unchang increas base case push bull
bear case valuat respect
note data june onward
note data septemb onward
note data januari onward
one-year forward histor price-to-earnings rel
note data juli onward
note data june onward
note data septemb onward
note data januari onward
issu ahead result
invest thesis/summari see long-term support
growth larg instal base ii stabl us reimburs iii
brightre drive higher resuppli iv on-going oper
leverag near term see two headwind row devic
segment growth low cycl period benefit
favor reimburs chang ii ep dilut verili
propel health invest
differ see less gm pressur
past year us reimburs stabl least
jan ii upsid penetr copd market via
portabl oxygen concentr propel health
long term iii recoveri row devic high-
growth period lap concomit higher resuppli
assumpt catalyst risk see high-single-
digit global mask growth mid-single-digit global devic
growth see gm improv
sg fall risk includ
tough comp row devic growth ii
gm fail stabilize/improv despit weak aud-
driven tailwind iii moder high row mask/resuppli
growth rate iv outcom competit bid round
exhibit us devic revenu growth
exhibit us mask accessori revenu
us revenu split product mask vs devic
devic total
masks/access total
exhibit morgan stanley expect result
issu ahead result
softer expect group revenu
mse healthcar sale mse industri sale
mse organ sale growth vs compani
target rang adjust ebit mse due healthcar
segment ebit lower mse industri ebit
ahead adj npat one-off after-tax includ
outlook ep guidanc current stand
downsid midpoint
mitig elev raw materi cost import tariff mse
refinitiv consensu estim
catalyst utilis substanti improv balanc sheet
headroom either capit manag
opportun share bought back pro
forma analysi suggest complet current share
buy-back could add ep valuat
upsid upsid compani
fulli follow state intent pursu value-
accret gener attract return
exhibit raw materi cost headwind
revers due lag impact
fibr engin yarn
compani data present research estim
exhibit actual mse
exhibit trail raw materi price still headwind
exhibit morgan stanley expect ann
issu ahead result
exhibit us growth shl peer
exhibit shl net debt debt cover profil mn
exhibit balanc sheet headroom acquisit
outlook result shl re-affirmed organ growth
guidanc higher ebitda fx provid new
guidanc inclus aurora acquisit underli
risk rais us scale
shl acquisit us-bas aurora diagnost purchas price
dri dec previou analysi transact
despit low revenu growth shl two largest us-
base peer compani saw organ constant-curr
growth boost hospit lab jv theme like on-going
mute somewhat anoth round pama
protect access medicar act
german oper environ like bottom german
organ growth inde flat although accord
channel check industri volum indic shl may
take market share caus slow growth germani
ebm referr bonu system partial
lap april return normal growth
like addit chang introduc last year caus
under-referr doctor led introduct
new code permit doctor refer patient certain test
without impact bonu
accret headroom deal remain even post
aurora acquisit result shl confirm intent
continu grow acquisit current
headroom exist facil aurora acquisit expand
us beachhead acquir busi pressur
us pama form jv hospit lab
exhibit morgan stanley expect shl
total path
total path
total path
total path
issu ahead result
exhibit gp contract type
exclud interest save capit rais day
npat guidanc rais due
interest save cash rais less spent
estim month contribut monteserrat
dorevitch patholog fair work determin expect
cost howev cost mitgat strategi
off-set chang guidanc
underli npat expect due soft
condit expect ebit uplift
product program patholog imag
lower unpat guidanc
lower midpoint requir unusu
larg split time manag expect market
condit improv second half
expect deliv save ebit uplift
includ guidanc expect
underli npat consensu bottom end
issu medic centr turnaround track august
result mark month sinc capit rais
hl announc turnaround strategi medic centr
increas full-tim equival joiner
recruit lag partial due higher
number resignations/retire expect expect
fte year-end short target assum pa
growth driven new joiner hl target
leaver left assum
improv resign assum
fte hsl target neg affect hl
revenu ebitda respect
increas gp bill per hour gross gp
bill per hour assum increas
await updat compani progress
doubl medic centr ebit ex day hospit
centr ex gp ebit fell
assum ebitda growth ebit growth ebit
growth support lower hcp amortis expens fewer
remain upfront-typ contract exhibit upsid
could driven elev gp activ due sever
fte gp contract type
hl share gp bill
compani data medicar australia morgan stanley research benefit data
exhibit capital-expenditure remain elev due patolog
upgrad project leapfrog initi addit payment
montserrat subject perform
issu jangho offer anoth consider jangho current hold hl
share made indic cash offer acquir remain share
per share hl reject offer asx announc
state propos opportunist fundament undervalu healiu
exhibit morgan stanley expect hl
revenu ebitda shown pre aasb chang restat account addit restat inform provid result
issu ahead result
australia hospit outlook remain challeng
coalit govern expect current industri condit
prevail phi rate increas hospit volum growth
although risk potenti phi rate increas cap
remov potenti volum benefit gener also
dissip think rhc get best cost
rise
franc uk stabl uk better cost go back
uk tariff price better chanc better volum
rhc took cost accommod weak observ
last year put cost back
still see capio strateg sound synergi come
overal see growth capio-acquir revenu pa
 lower australia histor see
long-term trend howev see rhc emerg second-
biggest oper european acut care scale benefit
procur staf see synergi rhc project rgd
level synergi within year howev synergi
slower expect given integr taken longer
exhibit volum price headwind drive structur
lower revenu outlook hospit
quarterli claim data roll
exhibit margin growth estim rhc australian hospit
share profit
exhibit morgan stanley expect rhc
issu ahead result
exhibit ci unit growth sustain lift post-recal four-
exhibit instal ci base continu grow
highlight share loss due advers product
cycl nucleu profil launch arrest trend
cochlear implant ci unit mse flat
tender sale like continu lose
market share profil launch gain
momentum full-year guidanc npat
audusd cent audeur requir
npat meet midpoint growth estim
assum cent audusd
audeur fx rate npat fall
provid insul new patient share loss sound
processor upgrad revenu grew cc
estim given continu acceler adopt
remain confid deliv sustain growth rate
provid insul downsid risk guidanc
sale immun short-term share shift estim
servic revenu growth flat
nucleu profil launch share loss temporari
launch germani april launch european
countri get registr us fda approv announc
along compani plan immedi us launch
think market share loss evid
temporari given nucleu profil put cochlear
equal foot mri compat competitor
also becom benchmark size thinnest implant
world implant reliabl neural interfac ii first partner
googl binaur audio stream nucleu
program avail uk trial nz facilit remot
follow-up appoint reduc burden
patient provid iv new app enabl forwardfocu
featur block sound behind help challeng hear environ
howev may still affect given earli launch day nucleu profil
especi us see return above-market ci unit growth mse
onward
chang channel sycl acquir may sycl audiolog
practic manag softwar pm use hear aid clinic across us
uk canada sycl provid direct link ha channel tradit
low referr rate ci channel develop market growth shift
adult senior awar penetr remain low format
cochlear provid network cpn sycl see increas rate
referr hear aid channel cpn
like grow time estim patient progress
severe/profound hear loss also custom sycl ha clinic
refer ci clinic implant increas patient captur would
add valu valuat
exhibit morgan stanley expect group
sale
sale
sale
exhibit morgan stanley expect segment specif
issu ahead result
ebit segment us mn
exhibit industri data show strong us ig growth
month
data repres month
exhibit product mix benefit carimmun wind-down
guidanc seqirus/behr mix provid
origin npat guidanc august result
constant fx result disclos
fx headwind still stand today
compani state would top end guidanc
cc actual time
august result indic formal
number seqiru flu busi would see margin
uplift profit base seqiru ebit
vs mse lead result
strongli look close
ebit guidanc mse one year earli
despit seqiru strength look genuin
move overal group seqiru behr guidanc although
expect better top rang
actual upgrad look
us behr deliv growth
albumin weigh growth say
seqiru ebit guidanc ebit still
stand guidanc time also expect
albumin issu ltd drag albumin china jun
reduc underli group npat
result forecast guid npat growth
strong busi momentum maintain
strong manag place see near-term
evid slowdown ig growth ig market remain
tight price increas continu given price mix cidp
approv ii on-going share gain idelvion iii haegarda
continu ramp competit threat materi
howev capital-expenditure remain elev capital-expenditure increas
almost within three year aim expand capac across
site guidanc expect remain elev across
multipl year capit project take time complet think yield
low
exhibit morgan stanley expect
exhibit morgan stanley expect product sale
issu ahead result
mvf expect npat uplift revenu mse
underli npat ms au treatment cycl
mse guidanc still anticip npat growth deliv moder
growth npat
headlin soft expect posit exit rate support
exclud impact key doctor departur mvf demonstr stimul
cycl growth vrt report cycl growth consist growth
low-cost growth premium servic ii total cycl
stimul cycl growth iii pre-implant genet screening/diagnosi
pg revenu declin expect approv launch non-invas pg
expect year may arrest declin
balanc sheet ok confid dividend sustain expect net
debt/ebitda improv mvf remain
within coven even maintain dividend yield ep pay-out
busi momentum post set continu first
clean growth period first full six month without depart key dr cycl
embed pcp given mvf saw growth sequenti
posit momentum busi howev note key
doctor non-compet claus expir septemb expect competit
re-emerg place risk expect
exhibit morgan stanley expect mvf
exhibit morgan stanley chang mvf estim
issu ahead result
vrt report result expect suggest risk well
revenu mse ebitda ms npat
ms australian fresh cycl mse guidanc
provid
australia cycl growth better expect driven lower-pr servic
medicar data sinc late vrt overal cycl activ increas vs
market growth four month nsw qld flat
ta vic grew respect low-cost activ fertil
centr increas revenu per cycl fell assum
rel stabl market share vrt go forward market growth
australian ebitda like predict low-cost volum
increas chang premium servic revenu mix lower-margin qld premium
servic increas higher-margin nsw premium servic decreas addit
cost associ reloc result ebitda vs mse
oper revenu miss expect irish cycl
manag expect recoveri ebitda fell
lower revenu higher bad debt provis singapor cycl fell ebitda
vs pcp denmark aagaard cycl fell due doctor staf
revenu fell vrt advis previous report includ
non-recur item sale line trianglen acquir exceed
manag expect total intern revenu mse ebitda
behind could risk expect
bottom like form cycl remain ow believ ivf industri
expand compound-annual-growth-rate long term though contrast mvf recent guidanc
question regard market growth could weigh vrt resolv
stock trade price-to-earnings high-single-digit earn growth ii fulli
frank dividend yield iii domin posit long-dur growth market
see valu stock remain ow
exhibit morgan stanley expect vrt
exhibit morgan stanley chang estim vrt
issu ahead result
exhibit diagnost imag growth yoy octob show return long-run
deliv npat well expect give us confid
outcom ebitda expect howev npat
ahead mse due mainli lower interest tax
similar perform expect still drive increas
npat season normal dictat stronger second half howev growth
like temper invest recruit anoth consider
full six-month impact remov gp-refer knee mri patient year
old mb sinc
new acquisit may continu perform slightli expect new zealand
radiolog asset contribut ebitda new geelong
practic forecast gener ebitda disclos separ group
ebitda within bound forecast bolster confid execut
integr asset
balanc sheet headroom remain acquisit forecast leverag fall
manag indic leverag target remain
impli may use potenti acquisit refer specialti
triniti cavendish acquir compris cash
equiti impli forecast ebitda
volum growth least risk volum weak associ
remov gp-refer knee mri patient mb expect
impact somewhat off-set addit mri prostat
remain ew rel small cap healthcar coverag list base case price
target valuat manag inde deliv
believ ew rate warrant stage given uncertain impact knee
mri remov mb patient integr risk relat recent
acquisit although remain track
exhibit morgan stanley expect
nb modelwar ep base npata report ep base npat
issu ahead result
result guidanc estim estia report ebitda
estim exclud royal commiss cost ep
mse ehe provid trade updat ebitda
inclus onetim fund benefit led us increas
ebitda expect fallen
balanc sheet remain ok flow oper convers ebitda
net debt remain similar juli level put ehe
ebitda undrawn facil balanc sheet posit
absorb fluctuat movement
focu remain develop ehe invest develop
come earn contribut develop
unlik materi cost depreci ramp ahead facil
matur return focus growth initi posit view ehe
plan capital-expenditure
maintain ew given downward revis ep estim short-term
concern regard occup unknown factor royal commiss
remain ew amongst small compani healthcar coverag see greater upsid
ow-rat mvf vrt
exhibit ms expect chang forecast
profit loss us mn
growth pcp
dep amort
growth pcp
abn extra tax
return asset
return equiti
fy sale
fy ebit
dep amort
gross cash op ns
inc dec wk cap
chg loan
net chg cash
profit loss mn
growth pcp
growth pcp
dep amort
growth pcp
abn extra tax
return asset
return equiti
fy sale
fy ebit
dep amort
gross cash op ns
inc dec wk cap
chg loan
net chg cash
profit loss mn
growth pcp
growth pcp
abn extra tax
return asset
return equiti
growth pcp
growth pcp
growth pcp
growth pcp
growth pcp
growth pcp
fy sale
fy ebit
dep amort
gross cash op ns
inc dec wk cap
chg loan
net chg cash
growth pcp
profit loss us mn
growth pcp
growth pcp
abn extra tax
return asset
return equiti
fy sale
 fy ebit
dep amort
gross cash op ns
inc dec wk cap
chg loan
net chg cash
profit loss
growth pcp
dep amort
growth pcp
abr extra tax
return asset
return equiti
fy sale
fy ebit
liquid leverag
dep amort
gross cash op ns
inc dec wk cap
chg loan
net chg cash
profit loss mn
growth pcp
growth pcp
abn extra tax
return asset
return equiti
growth pcp
growth pcp
growth pcp
growth pcp
fy sale
fy ebit
dep amort
gross cash op ns
inc dec wk cap
chg loan
net chg cash
profit loss mn
growth pcp
dep amort
growth pcp
abn extra tax
return asset
return equiti
fy sale
fy ebit
dep amort
gross cash op ns
inc dec wk cap
chang issu capit
chg loan
net chg cash
profit loss mnn
growth pcp
dep amort
growth pcp
return asset
return equiti
fy sale
fy ebit
dep amort
gross cash op ns
inc dec wk cap
chg loan
net chg cash
profit loss
growth pcp
growth pcp
abn extra tax
return asset
return equiti
growth pcp
growth pcp
growth pcp
growth pcp
growth pcp
growth pcp
growth pcp
fy sale
 fy ebit
dep amort
gross cash op ns
inc dec wk cap
chg loan
net chg cash
note provid research coverag list cdi associ underli ordinari share compani courtesi may includ cdi price target cdi share price aud
dollar research report unless otherwis state cdi price target convers calcul use appropri currenc exchang rate ordinari share versu cdi ratio investor awar
calcul take account issu risk associ invest cdi includ limit liquid vote right dividend volatil currenc exchang rate fluctuat
profit loss mn
growth pcp
growth pcp
return asset
return equiti
avail distributor
fy sale
 fy ebit
dep amort
gross cash op ns
inc dec wk cap
chg loan
net chg cash
profit loss
growth pcp
dep amort
growth pcp
abr extra tax
return asset
return equiti
liquid leverag ratio
 fy sale
fy ebit
dep amort
gross cash op ns
inc dec wk cap
chg loan
net chg cash
profit loss mn
growth pcp
growth pcp
abn extra tax
return asset
return equiti
fy sale
 fy ebit
dep amort
gross cash op ns
inc dec wk cap
net chg cash
chg loan
chang work capit
chang net debt
depreci amortis
op profit tax
op profit tax
valuat methodolog risk
believ price target base premium ann histor price-to-earnings rel
ex-financi appropri better reflect favour
posit characterist stock non-financi healthcar compani
off-shore earn exposur averag discount last five year
howev sinc compani result believ stock could trade closer
still discount index deliveri result provid confid
execut demonstr posit growth trend organ growth
expect ii guidanc ep encapsul risk associ
elev input cost chines import tariff iii buy-back on-going see
mid-single-digit ep accret iv exist potenti portfolio optim
via capit manag
appli discount price-to-earnings industri ex-financi index
estim ep ann translat audusd result
base case valuat price target move
updat index multipl date last public februari
audusd previous use
downsid risk price target
industri product currenc euro-zon weaken
downturn us economi
scarciti disrupt natur synthet rubber suppli
price target deriv base-cas scenario dcf
assum wacc termin growth rate
pb growth faster forecast market share lost new player execut risk
minim store roll-out
price target deriv base-cas scenario dcf
assum wacc termin growth rate
risk achiev price target
upsid faster roll-out nucleu profil weaken higher
penetr upgrad market
downsid reimburs restrict us develop eu strengthen
disappoint uptak new product
price target deriv base-cas scenario dcf
assum wacc termin growth rate
potenti announc acquisit biotech/vaccines/immunolog
ii industri de-stock possibl price increas
iii uptak kcentra us
lower-than-expect adopt next-gener rcoag product
ii appreci aud usd
iii chang us reimburs environ
base case valuat calcul use dcf wacc lt growth rate
set price target equal base case
achiev higher bond penetr higher averag valu
execut integr gener earn growth
royal commiss result industri chang benefit ehe
stricter regul result royal commiss
reput damag estia name royal commiss
reduct balanc
capital-expenditure requir increas fund avail capac
base case dcf assum wacc termin
growth rate price target set equal base case
report reduc gp acquisit cost concomit increas gp number
return gp rebat index
better expect di patholog fee growth
inabl recruit plan number doctor
integr montserrat day hospit upon transact complet
failur off-set wage increas patholog via collect centr closur
base case dcf valuat form basi price target assum
wacc termin growth rate
downsid risk price target includ
fee cut australian govern domest patholog
integr risk acquisit synergi fail materialis
depreci gbp appreci aud
risk-reward view input cost fx still swing factor
risk-reward view input cost fx still swing factor
base histor price-to-earnings rel industri ex-financi
appli base case ep
full use asset sale proce buy-back add per share currenc
revers lower latex price
natur latex cost averag long term eur persist current level
asian cost currenc ann achiev underli organ ebit growth
pressur industri busi base case assum low-single-digit
organ revenu growth bear-cas scenario assum neg revenu
synthet latex cost higher forecast highlight
assum pass-through increas cost end-us
think ann justifi trade least
line ex-financi given
greater transpar fx ii input cost iii
organ growth target ann guidanc
iv capit management/m potenti
ep growth continu busi
expect stock outperform
australian healthcar name given
defens characterist low exposur
australian credit/consum crunch
leverag fall aud
strength global manufactur
ann abil gain market share
price key input natur rubber
balanc sheet posit room either
return cash sharehold draw
borrow acquisit
movement input cost indic
macro industri product data
us europ
risk achiev price
industri product currenc
eurozon weaken downturn us
economi scarciti disrupt natur
synthet rubber suppli
exhibit ann bull bear organ growth cog benefit key
synergi
shwb
sale
morgan stanley research impli valuat convert aud/usd
dcf valuat impli share close fulli valu
dcf valuat impli share close fulli valu
pb growth pricelin store peak api/sig merger upsid
compound-annual-growth-rate pb growth pb market share remain flat
pb growth pb market share loss direct distribut
exhibit bull bear case retail roll-out custom market share key
pb growth
share
market share
short-term regulatori risk
dampen via believ futur
potenti deregul australian
pharmaceut industri materi
disrupt expos stock deserv
trade discount asx
small cap univers prefer hold
stock lower risk steadier growth
trajectori monash ivf
pb long-term growth moder
despit price reform share loss
distribut busi revenu
competitor evid
growth rate pb outlay
share gain sip
disclosur announc pb
